-
公开(公告)号：US20200071669A1
公开(公告)日：2020-03-05
申请号：US16490568
申请日：2018-03-02
申请人： Yeda Research and Development Co. Ltd. , The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
发明人： Benjamin GEIGER , Nir FRIEDMAN , Shimrit LIEBER , Zelig ESHHAR , Tova WAKS , An at GLOBERSON LEVIN
IPC分类号： C12N5/0783 , A61K35/17
摘要： Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.
-
2.发明申请公开(公告)号：US20200368322A1
公开(公告)日：2020-11-26
申请号：US16986473
申请日：2020-08-06
发明人： Benjamin GEIGER , Eran ELINAV , Inna GROSHEVA
摘要： A method of treating a disease associated with intestinal barrier dysfunction in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which downregulates the amount of glucose in intestinal cells, with the proviso that the disease is not Diabetes or obesity. Other agents for treating diseases associated with intestinal barrier dysfunction are also disclosed.
-
公开(公告)号：US20230364062A1
公开(公告)日：2023-11-16
申请号：US18134064
申请日：2023-04-13
发明人： Liran SHLUSH , Tom FLEISCHER , Benjamin GEIGER , Minhua SU
IPC分类号： A61K31/426 , C12Q1/6827 , A61P35/02
CPC分类号： A61K31/426 , C12Q1/6827 , A61P35/02
摘要： A method is disclosed for treating or preventing a myeloid malignancy in a subject harboring a mutation in SRSF2 comprising:
(a) analyzing in a sample of the subject for the presence of an SRSF2 mutation; and
(b) administering to the subject a therapeutically effective amount of a Rho Kinase inhibitor, or an inhibitor of a downstream effector thereof, upon identification of SRSF2 mutation.-
公开(公告)号：US20160166582A1
公开(公告)日：2016-06-16
申请号：US15050502
申请日：2016-02-23
发明人： Irina LAVELIN , Varda ROTTER , Moshe OREN , Ami NAVON , Zvi KAM , Benjamin GEIGER
IPC分类号： A61K31/555 , G01N33/50 , C07K14/47 , A61K31/522 , A61K31/47
CPC分类号： A61K31/555 , A61K31/47 , A61K31/52 , A61K31/522 , A61K31/60 , A61K33/34 , C07K14/4746 , C07K2319/40 , C07K2319/60 , C12N9/6421 , C12Y304/25001 , G01N33/5035
摘要： A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.
-
-
-
搜索结果
4 条记录 (耗时 0.031 秒)
